Search Results

Your search for M. Catherine Pietanza, MD matches 2 pages

Showing 1 - 2

By M. Catherine Pietanza, MD / 2015 European Cancer Congress

M. Catherine Pietanza, MD, on A Promising New Agent for SCLC

M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).

issues in oncology

lung cancer

By The ASCO Post Staff / Wednesday, September 30, 2015 9:28 AM

ECC 2015: First Targeted Treatment for Small Cell Lung Cancer Shows Promise

Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently diagnosed only when it has metastasized. Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only 6%. Researchers presented novel findings (Abstract...

Apr

Today In Oncology

Search Results

Your search for M. Catherine Pietanza, MD matches 2 pages

M. Catherine Pietanza, MD, on A Promising New Agent for SCLC

ECC 2015: First Targeted Treatment for Small Cell Lung Cancer Shows Promise

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer